Riskpilot← Back to searchSign inGet full accessGLAXOSMITHKLINE HOLDING AS
ASActiveOrg 919157445Drammensveien 288, 0283 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 19670 employees
Revenue 2024
NOK 0
EBITDA margin
—
Equity ratio
65.4%
Financial strength
Net profit 2024
NOK 22,7M
+19% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK 0 | — |
| Net profit | NOK 22,7M | +19% |
| Total assets | NOK 276,9M | +1% |
| Equity | NOK 181,2M | +0% |
| Employees | 0 | — |
Legal name
GLAXOSMITHKLINE HOLDING AS
Org number
919157445
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. oktober 1967
Share capital
NOK 170 168 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Drammensveien 288, 0283 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 0 | 0 | 0 | 0 | 0 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 0 | 0 | 0 | 0 |
| Net financials | 19 000 | 20 500 | 19 000 | 19 039 | 22 700 |
| Profit before tax | 19 000 | 20 500 | 19 000 | 19 039 | 22 700 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 19 000 | 20 500 | 19 000 | 19 039 | 22 700 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 272 836 | 274 086 | 272 586 | 273 200 | 276 861 |
| Equity | 181 202 | 181 202 | 181 202 | 181 202 | 181 202 |
| Long-term debt | 53 758 | 72 384 | 72 384 | 72 959 | 70 809 |
| Short-term debt | 37 876 | 20 500 | 19 000 | 19 039 | 24 850 |
| Total debt | 91 634 | 92 884 | 91 384 | 91 999 | 95 659 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
65.4%
This company
38.2%
Market median
+71% vs market
20202024
Return on equity
12.5%
This company
18.4%
Market median
+32% vs market
20202024
Net profit margin
2270000000.0%
This company
8.1%
Market median
+28024691258% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.53×
This company
0.62×
Market median
+15% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
AE Chief Executive Officer | Chief Executive Officer | 2023 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (2) | ||
| Board of Directors | 2021 – 2023 | |
| Chairman | 2021 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Setfirst Limited | Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GLAXOSMITHKLINE HOLDING AS 
GLAXOSMITHKLINE ASBoard members of GLAXOSMITHKLINE HOLDING AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Akalin Erin Omur | Chief Executive Officer | 0 companies |
| Tetiana Luczkiw | Board of Directors | 0 companies |
| Paolo Chiesa | Board of Directors | 0 companies |
| Christian Probst | Chairman | 0 companies |
| Omur Akalin Erin | Chairman | 0 companies |